Bios Partners

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Opus Genetics is a gene therapy company focused on addressing challenges related to the manufacturing of treatments for ultra-rare retinal degenerative diseases. By utilizing adeno-associated virus-based gene therapies, Opus aims to provide effective solutions for individuals suffering from blinding conditions. The company's patient-first approach emphasizes the importance of accessibility to these specialized treatments, ensuring that advancements in gene therapy reach those in need efficiently.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) for the treatment of various conditions, including Alzheimer’s disease, bipolar disorder, type II diabetes, inflammatory diseases, and several high-impact cancers such as glioblastoma, ovarian, breast, and pancreatic cancers. Actuate is advancing its lead compound, elraglusib (formerly known as 9-ING-41), which is designed to inhibit GSK-3β and disrupt cancer cell survival and growth. The company has demonstrated promising anti-tumor activity in preclinical models, particularly for difficult-to-treat cancers. Actuate Therapeutics aims to discover, develop, and commercialize new therapeutic agents that address significant unmet medical needs in oncology and neurodegeneration.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing treatments for niche orphan drug indications related to lung injury and disease, particularly emphasizing fibrosis. The company is advancing several drug candidates, including LTI-01, an injectable fibrinolytic treatment aimed at clearing scar tissue in the lungs to improve fluid drainage and reduce complications associated with loculated pleural effusion, a severe complication of pneumonia. Additionally, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis. By targeting these specific conditions, the company aims to enhance clinical pathways and provide effective solutions for patients suffering from debilitating lung diseases. Established in 2012 and headquartered in Austin, Texas, Lung Therapeutics serves a global network of patients, healthcare providers, partners, and investors.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) for the treatment of various conditions, including Alzheimer’s disease, bipolar disorder, type II diabetes, inflammatory diseases, and several high-impact cancers such as glioblastoma, ovarian, breast, and pancreatic cancers. Actuate is advancing its lead compound, elraglusib (formerly known as 9-ING-41), which is designed to inhibit GSK-3β and disrupt cancer cell survival and growth. The company has demonstrated promising anti-tumor activity in preclinical models, particularly for difficult-to-treat cancers. Actuate Therapeutics aims to discover, develop, and commercialize new therapeutic agents that address significant unmet medical needs in oncology and neurodegeneration.

IN8bio, Inc. is a clinical-stage biotechnology company based in New York that specializes in developing innovative therapies for cancer treatment, utilizing gamma-delta T cells. These immune cells possess unique properties that allow them to differentiate between healthy and diseased tissues. The company is currently conducting two Phase 1 clinical trials for its lead product candidates: INB-200, a genetically modified autologous gamma-delta T cell therapy aimed at treating newly diagnosed glioblastoma, and INB-100, an allogeneic therapy for patients with acute leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a diverse portfolio of preclinical programs targeting various solid tumor types, further expanding its commitment to advancing cell-based immunotherapies. Founded in 2016 and previously known as Incysus Therapeutics, IN8bio continues to focus on harnessing the potential of gamma-delta T cells to improve cancer treatment outcomes.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing treatments for niche orphan drug indications related to lung injury and disease, particularly emphasizing fibrosis. The company is advancing several drug candidates, including LTI-01, an injectable fibrinolytic treatment aimed at clearing scar tissue in the lungs to improve fluid drainage and reduce complications associated with loculated pleural effusion, a severe complication of pneumonia. Additionally, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis. By targeting these specific conditions, the company aims to enhance clinical pathways and provide effective solutions for patients suffering from debilitating lung diseases. Established in 2012 and headquartered in Austin, Texas, Lung Therapeutics serves a global network of patients, healthcare providers, partners, and investors.

Lantern Pharma Inc. is a clinical stage biotechnology company based in Dallas, Texas, specializing in precision oncology therapeutics. The company employs artificial intelligence and machine learning to develop innovative cancer treatments and to revitalize abandoned drug candidates. Its lead drug candidate, LP-100, is currently undergoing phase II clinical trials for metastatic, castration-resistant prostate cancer. Additionally, Lantern is developing LP-300 as a combination therapy for female non-smokers diagnosed with non-small cell lung cancer adenocarcinoma. The firm is also advancing LP-184, a preclinical drug candidate designed to target cancer cells that overexpress specific biomarkers. Lantern Pharma utilizes its proprietary RADR platform to address challenges in oncology drug development, such as patient stratification and understanding mechanisms of action, thereby aiming to accelerate the development of personalized cancer therapies.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.